Article Abstract

ciRS-7 acts as a master player in colorectal cancer

Authors: Deborah Morena, Riccardo Taulli


Colorectal cancer (CRC) represents a critical health burden worldwide (1,2). Although patients with localized CRC have a 5-year survival rate of about 90%, this ratio dramatically drops in patients with metastatic tumors (2). Standard and liquid biopsy are extremely effective for the identification of critical genetic lesions and to study clonal evolution in CRC (3,4). However, only a minor fraction of oncogenic mutations are clinically actionable, indicating that other novel therapeutic strategies are urgently needed.